In September 2026, the University of Melbourne joined the Structural Genomics Consortium, becoming Australasia's first affiliated site in a global effort to map pharmacological tools for every human protein by 2035. The initiative, called Target 2035, wagers that artificial intelligence — trained on vast, openly shared experimental data — can transform drug discovery from costly guesswork into informed prediction. At its heart, the endeavor is a quiet revolution in how humanity organizes the search for healing: away from proprietary isolation and toward coordinated, collective knowledge.
Melbourne Joins Global Drug Discovery Consortium to Accelerate AI-Driven Medicine Development
The initiative addresses rare diseases affecting approximately 1 in 12 people globally, with potential to develop treatments for patients currently lacking therapeutic options.